DXCM Dexcom Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
21:56
May 21
TheValueist Founder, Atlas Peak Research
Long medtech and digital health names as rising semiconductor content in medical devices drives growth in imaging, monitoring, robotics, and wearables.
DXCM
HIGH
12:24
May 15
zerohedge Financial blog / news aggregator
Activist investor Elliott Investment Management took a stake in Dexcom (DXCM) and reached a settlement.
DXCM
HIGH
12:21
May 15
Newsquawk Newswire (@Newsquawk)
Elliott Investment Management disclosed a long stake in DexCom (DXCM).
DXCM
HIGH
20:22
May 14
Bloomberg Newswire (@business)
Activist investor Elliott Management disclosed a long stake in Dexcom (DXCM) and will place two independent directors on the board.
DXCM
HIGH
20:15
May 04
TheLAPurchaser L/S Equity trader
The tweet is a brief reply mentioning Dexcom stock without any directional opinion, forecast, or market context.
DXCM
HIGH
00:43
May 01
TheLAPurchaser L/S Equity trader
Bearish view on DXCM as maturing CGM market, single-product risk, and GLP-1 headwinds drive multiple compression similar to RMD.
DXCM
HIGH
00:27
May 01
TheLAPurchaser L/S Equity trader
Avoid or short DXCM because its core business is decelerating in a maturing market, making the T2 NIT CMS approval insufficient to justify ownership.
DXCM
HIGH
00:26
May 01
TheLAPurchaser L/S Equity trader
The author criticizes owning Dexcom for a T2 NIT CMS approval while core growth slows, signaling a maturing market and downside risk.
DXCM
HIGH
00:26
May 01
TheLAPurchaser L/S Equity trader
The author warns that owning Dexcom for a T2 NIT CMS approval is misguided because the core business is slowing in a maturing market, signaling a bearish outlook.
DXCM
HIGH
00:19
May 01
TheLAPurchaser L/S Equity trader
Bearish view on medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
DXCM
HIGH
11:43
Apr 22
TheLAPurchaser L/S Equity trader
Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures for ISRG signal that GLP-1 drugs are reducing demand for related medical devices and services, extending to diabetes management and respiratory care.
DXCM
HIGH
11:42
Apr 22
TheLAPurchaser L/S Equity trader
Bearish view on DXCM and RMD because accelerating declines in bariatric procedures due to GLP-1 drug adoption signal a structural headwind for companies exposed to obesity and diabetes-related treatment demand.
DXCM 1ST
HIGH

About DXCM Analyst Coverage

Buzzberg tracks DXCM (Dexcom) across 5 sources. 0 bullish vs 0 bearish calls from 5 analysts. Sentiment: evenly split. 12 total trade ideas tracked.